See more : Nexity Financial Corporation (NXTYQ) Income Statement Analysis – Financial Results
Complete financial analysis of Nektar Therapeutics (NKTR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nektar Therapeutics, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Proterra Inc. (PTRA) Income Statement Analysis – Financial Results
- Jilin Sino-Microelectronics Co., Ltd. (600360.SS) Income Statement Analysis – Financial Results
- Zenith Fibres Limited (ZENIFIB.BO) Income Statement Analysis – Financial Results
- Chesapeake Energy Corporation (CHKEW) Income Statement Analysis – Financial Results
- Gordon Auto Body Parts Co., Ltd. (1524.TW) Income Statement Analysis – Financial Results
Nektar Therapeutics (NKTR)
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 90.12M | 92.06M | 101.91M | 152.92M | 114.62M | 1.19B | 307.71M | 165.44M | 230.78M | 200.71M | 148.92M | 81.19M | 71.48M | 159.04M | 71.93M | 90.19M | 273.03M | 217.72M | 126.28M | 114.27M | 106.26M | 94.85M | 77.47M | 51.63M | 41.36M | 21.80M | 16.25M | 6.90M | 3.40M | 1.70M |
| Cost of Revenue | 36.64M | 21.64M | 24.90M | 19.48M | 21.37M | 24.41M | 30.55M | 30.22M | 34.10M | 28.53M | 38.51M | 30.43M | 21.89M | 25.67M | 30.95M | 35.04M | 147.52M | 118.09M | 36.00M | 19.80M | 14.68M | 7.02M | 4.17M | 0.00 | 0.00 | 0.00 | 0.00 | -1.20M | -1.10M | -500.00K |
| Gross Profit | 53.48M | 70.42M | 77.01M | 133.44M | 93.24M | 1.17B | 277.16M | 135.22M | 196.68M | 172.17M | 110.41M | 50.76M | 49.59M | 133.37M | 40.98M | 55.15M | 125.51M | 99.63M | 90.28M | 94.47M | 91.58M | 87.83M | 73.30M | 51.63M | 41.36M | 21.80M | 16.25M | 8.10M | 4.50M | 2.20M |
| Gross Profit Ratio | 59.34% | 76.50% | 75.57% | 87.26% | 81.35% | 97.95% | 90.07% | 81.74% | 85.22% | 85.78% | 74.14% | 62.52% | 69.37% | 83.86% | 56.98% | 61.15% | 45.97% | 45.76% | 71.49% | 82.67% | 86.19% | 92.60% | 94.62% | 100.00% | 100.00% | 100.00% | 100.00% | 117.39% | 132.35% | 129.41% |
| Research & Development | 114.16M | 218.32M | 400.27M | 408.68M | 434.57M | 399.54M | 268.46M | 203.80M | 182.79M | 147.73M | 190.01M | 148.68M | 126.77M | 108.07M | 95.11M | 154.42M | 153.58M | 149.38M | 151.66M | 133.52M | 131.53M | 157.38M | 139.65M | 101.54M | 64.08M | 35.40M | 23.65M | 14.40M | 9.00M | 0.00 |
| General & Administrative | 77.42M | 92.33M | 122.84M | 104.68M | 98.71M | 81.44M | 52.36M | 44.28M | 43.27M | 40.93M | 40.53M | 41.61M | 46.76M | 40.99M | 41.01M | 51.50M | 56.34M | 78.32M | 43.85M | 30.97M | 22.02M | 26.02M | 18.86M | 13.93M | 7.87M | 8.39M | 6.33M | 4.00M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 77.42M | 92.33M | 122.84M | 104.68M | 98.71M | 81.44M | 52.36M | 44.28M | 43.27M | 40.93M | 40.53M | 41.61M | 46.76M | 40.99M | 41.01M | 51.50M | 56.34M | 78.32M | 43.85M | 30.97M | 22.02M | 26.02M | 18.86M | 13.93M | 7.87M | 8.39M | 6.33M | 4.00M | 3.20M | 7.40M |
| Other Expenses | 0.00 | -116.00K | -24.41M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 392.00K | 983.00K | 0.00 | 0.00 | 0.00 | -68.11M | -48.25M | 31.16M | 69.55M | 3.92M | 4.22M | 4.51M | 25.49M | 0.00 | 0.00 | 0.00 | 0.00 | 1.20M | 4.30M | 7.90M |
| Operating Expenses | 190.90M | 310.66M | 523.11M | 513.36M | 533.28M | 480.98M | 320.83M | 248.08M | 226.05M | 188.66M | 230.54M | 190.29M | 173.53M | 149.05M | 136.12M | 137.80M | 161.66M | 258.86M | 265.06M | 168.41M | 157.76M | 187.91M | 184.00M | 115.48M | 71.95M | 43.79M | 29.97M | 19.60M | 13.30M | 7.90M |
| Cost & Expenses | 227.55M | 332.29M | 548.01M | 532.84M | 554.65M | 505.39M | 351.37M | 278.29M | 260.16M | 217.19M | 269.05M | 220.72M | 195.42M | 174.72M | 167.06M | 172.84M | 309.18M | 376.95M | 301.05M | 188.21M | 172.44M | 194.93M | 188.17M | 115.48M | 71.95M | 43.79M | 29.97M | 18.40M | 12.20M | 7.40M |
| Interest Income | 19.01M | 6.67M | 2.57M | 18.28M | 46.34M | 37.57M | 4.52M | 2.39M | 1.68M | 814.00K | 732.00K | 2.32M | 2.24M | 1.55M | 3.69M | 12.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 25.33M | 28.91M | 47.31M | 37.12M | 46.35M | 42.78M | 40.95M | 42.18M | 38.90M | 38.76M | 40.76M | 33.55M | 10.22M | 11.17M | 12.18M | 15.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 7.82M | 12.20M | 13.00M | 12.50M | 11.00M | 8.80M | 12.60M | 13.20M | 12.86M | 12.93M | 14.28M | 14.51M | 14.95M | 16.55M | 14.88M | 22.49M | 28.15M | 32.64M | 26.23M | 19.19M | 18.42M | 18.97M | 40.39M | 10.12M | 7.25M | 3.60M | 2.44M | 1.20M | 1.10M | 500.00K |
| EBITDA | -243.11M | -323.87M | -462.97M | -394.33M | -382.70M | 734.30M | -42.52M | -97.27M | -29.37M | -2.74M | -106.01M | -124.10M | -107.79M | -9.33M | -75.72M | 2.54M | -7.12M | -125.72M | -147.07M | -54.76M | -47.77M | -81.11M | -70.32M | -53.72M | -23.34M | -18.39M | -11.29M | -10.30M | -7.70M | -5.20M |
| EBITDA Ratio | -269.75% | -239.57% | -445.31% | -227.22% | -332.01% | 61.71% | -7.93% | -57.49% | -6.43% | -1.37% | -70.33% | -149.92% | -149.33% | 1.52% | -106.44% | -197.91% | -21.36% | -46.66% | -58.44% | -40.07% | -75.27% | -84.47% | 103.45% | -22.74% | -32.52% | -84.39% | -69.46% | -172.46% | -264.71% | -341.18% |
| Operating Income | -137.43M | -240.24M | -446.10M | -379.92M | -440.04M | 687.93M | -59.64M | -112.86M | -29.37M | -16.49M | -120.13M | -141.20M | -123.94M | -28.26M | -95.13M | -82.65M | -36.15M | -159.23M | -182.63M | -73.94M | -66.19M | -100.08M | -256.96M | -66.14M | -40.48M | -21.99M | -13.72M | -11.50M | -8.80M | -5.70M |
| Operating Income Ratio | -152.49% | -260.97% | -437.76% | -248.45% | -383.92% | 57.65% | -19.38% | -68.22% | -12.73% | -8.21% | -80.67% | -173.91% | -173.39% | -17.77% | -132.25% | -91.65% | -13.24% | -73.14% | -144.63% | -64.71% | -62.29% | -105.52% | -331.70% | -128.10% | -97.89% | -100.89% | -84.46% | -166.67% | -258.82% | -335.29% |
| Total Other Income/Expenses | -138.83M | -124.75M | -77.18M | -64.03M | -19.00K | -5.21M | -36.43M | -39.79M | -51.30M | -37.94M | -39.64M | -30.25M | -9.02M | -8.80M | -7.64M | 47.51M | 4.70M | 5.30M | -2.62M | -28.11M | 19.67M | -7.39M | 6.96M | -31.26M | -9.89M | 0.00 | 0.00 | 1.60M | 1.30M | 600.00K |
| Income Before Tax | -276.26M | -364.98M | -523.28M | -443.95M | -440.05M | 682.73M | -96.08M | -152.65M | -80.67M | -54.43M | -159.77M | -171.45M | -132.96M | -37.06M | -102.77M | 35.14M | -31.45M | -153.93M | -185.25M | -102.05M | -46.51M | -107.47M | -250.01M | -97.40M | -50.37M | 0.00 | 0.00 | -9.90M | -7.50M | -5.10M |
| Income Before Tax Ratio | -306.54% | -396.48% | -513.49% | -290.32% | -383.93% | 57.21% | -31.22% | -92.27% | -34.96% | -27.12% | -107.28% | -211.17% | -186.01% | -23.30% | -142.88% | 38.97% | -11.52% | -70.70% | -146.70% | -89.31% | -43.77% | -113.31% | -322.72% | -188.66% | -121.80% | 0.00% | 0.00% | -143.48% | -220.59% | -300.00% |
| Income Tax Expense | -200.00K | 3.22M | 557.00K | 493.00K | 613.00K | 1.41M | 616.00K | 876.00K | 506.00K | -512.00K | 2.25M | 406.00K | 1.02M | 881.00K | -253.00K | -806.00K | 1.31M | 828.00K | -137.00K | -163.00K | 169.00K | 7.39M | 139.31M | 33.56M | 7.85M | -3.63M | -3.74M | -1.50M | -1.10M | -400.00K |
| Net Income | -276.06M | -368.20M | -523.84M | -444.44M | -440.67M | 681.31M | -96.69M | -153.52M | -81.18M | -53.92M | -162.01M | -171.86M | -133.98M | -37.94M | -102.52M | -34.34M | -32.76M | -154.76M | -185.11M | -101.89M | -46.68M | -107.47M | -250.01M | -97.40M | -38.45M | -18.36M | -9.98M | -10.00M | -7.70M | -5.30M |
| Net Income Ratio | -306.31% | -399.98% | -514.03% | -290.65% | -384.47% | 57.09% | -31.42% | -92.80% | -35.17% | -26.86% | -108.79% | -211.67% | -187.43% | -23.85% | -142.52% | -38.07% | -12.00% | -71.08% | -146.59% | -89.16% | -43.93% | -113.31% | -322.72% | -188.66% | -92.96% | -84.22% | -61.44% | -144.93% | -226.47% | -311.76% |
| EPS | -1.45 | -1.97 | -2.86 | -2.49 | -2.52 | 3.78 | -0.62 | -1.10 | -0.61 | -0.42 | -1.40 | -1.50 | -1.19 | -0.40 | -1.11 | -0.37 | -0.36 | -1.72 | -2.15 | -1.30 | -0.84 | -1.94 | -4.71 | -2.32 | -1.13 | -0.58 | -0.36 | -0.44 | -0.39 | -0.43 |
| EPS Diluted | -1.45 | -1.97 | -2.86 | -2.49 | -2.52 | 3.78 | -0.62 | -1.10 | -0.61 | -0.42 | -1.40 | -1.50 | -1.19 | -0.40 | -1.11 | -0.37 | -0.36 | -1.72 | -2.15 | -1.30 | -0.84 | -1.94 | -4.71 | -2.32 | -1.13 | -0.58 | -0.36 | -0.44 | -0.39 | -0.43 |
| Weighted Avg Shares Out | 190.00M | 187.14M | 183.30M | 178.58M | 174.99M | 180.12M | 155.95M | 139.57M | 132.46M | 126.87M | 115.73M | 114.82M | 112.94M | 94.08M | 92.77M | 92.41M | 91.88M | 89.79M | 85.92M | 78.46M | 55.82M | 55.28M | 53.14M | 42.00M | 34.02M | 31.44M | 27.58M | 22.73M | 19.74M | 12.33M |
| Weighted Avg Shares Out (Dil) | 190.00M | 187.14M | 183.30M | 178.58M | 174.99M | 180.12M | 155.95M | 139.60M | 132.46M | 126.87M | 115.73M | 114.82M | 112.94M | 94.08M | 92.77M | 92.41M | 91.88M | 89.79M | 85.92M | 78.46M | 55.82M | 55.28M | 53.14M | 42.00M | 34.02M | 31.44M | 27.58M | 22.73M | 19.74M | 12.33M |
Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting
– NKTR-255 Combination Expanded NK Cells and Enhanced ADCC Against Rituximab-Resistant Burkitt Lymphoma (BL) Cells – SAN FRANCISCO , Dec. 11, 2023 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced that collaborators from the Cairo Laboratory at New York Medical College presented a poster...
Nektar (NKTR) Up 4% Since Last Earnings Report: Can It Continue?
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock?
Nektar Therapeutics (NKTR) Incurs Wider-Than-Expected Q3 Loss
Nektar (NKTR) misses third-quarter estimates for the bottom line but beats the same for the top line.
Nektar Therapeutics (NKTR) Q3 2023 Earnings Call Transcript
Nektar Therapeutics (NASDAQ:NKTR ) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Vivian Wu - Director, IR and Corporate Affairs Howard Robin - President and CEO Jonathan Zalevsky - Chief, Research and Development Mary Tagliaferri...
Nektar Therapeutics Reports Third Quarter 2023 Financial Results
SAN FRANCISCO , Nov. 7, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2023. Cash and investments in marketable securities at September 30, 2023, were $372.7 million as compared to...
Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets
SAN FRANCISCO , Oct. 31, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2023 on Tuesday, November 7, 2023, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive...
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?
Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress
– Dose-Dependent Efficacy Reported Across All Endpoints for REZPEG Demonstrating a Rapid Onset of Action and Continuing Benefit for 36 Weeks After 12-Week Treatment Period – – New Data Presented Show Encouraging Proportion of Patient-Reported Responder Outcomes for DLQI and...
Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy
– Phase 1b Safety and Efficacy Data for Rezpegaldesleukin in Moderate to Severe Atopic Dermatitis to be Presented in Late-Breaking Oral Presentation – SAN FRANCISCO , Oct. 2, 2023 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will have...
Nektar (NKTR), Cellular Biomedicine Join for Lung Cancer Studies
Nektar (NKTR) enters into a deal with Cellular Biomedicine Group to develop NKTR-255 in combination with C-TIL05 to treat advanced NSCLC.
Source: https://incomestatements.info
Category: Stock Reports